Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Tectonic Therapeutic, Inc. (TECX) is the issuer of common stock that Terrance Gerard McGuire, a former director, has notified for resale under Rule 144. The notice covers a proposed sale of 7,513 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $276,718.06 and reference to 19,549,366 shares outstanding as of the notice date. The shares relate to a stock option exercise from the issuer, with cash payment on August 27, 2026. The filing also reports that McGuire previously sold 10,200 shares of common stock during the past three months for $383,670.96 on August 21, 2026.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Scientific Officer Peter McNamara exercised options and sold shares on August 25, 2026 under a Rule 10b5-1 trading plan. He exercised 43 options at an exercise price of $14.71 per share into 43 shares of common stock, then sold those 43 common shares in a sale transaction at $36.52 per share. Following the exercise, 7,787 stock options remained outstanding from this grant, which vests in 48 equal monthly installments beginning October 25, 2025.
Tectonic Therapeutic, Inc. (TECX) is the subject of a notice under Rule 144 filed for the account of former director Terrance McGuire. The notice states an intention to sell 10,200 shares of common stock, to be acquired through a stock option exercise for cash and sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $383,670.96. The filing lists 19,549,366 shares of common stock outstanding and a proposed sale date of 08/21/2026 on NASDAQ.
Tectonic Therapeutic, Inc. Chief Scientific Officer Peter McNamara exercised options for 43 shares of common stock at an exercise price of $14.71 per share and immediately sold 43 shares of common stock at $35.00 per share on August 12, 2026. Following the option exercise, he held 7,830 employee stock options directly. The exercise and subsequent sale were carried out under a Rule 10b5-1 trading plan adopted on November 14, 2025.
TECX filed a Form 144 notice for a planned sale of common stock. The filing lists 129 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on August 12, 2026, with an indicated market value of $4,111.23 and listing on NASDAQ. The shares are to be sold after acquisition via an exercise of stock options for cash. The filing also notes a prior 10b5-1 sale by Peter McNamara of 172 shares of common stock on June 30, 2026 for $6,020.00.
Tectonic Therapeutic, Inc., a clinical-stage biotech focused on GPCR-targeted biologics using its GEODe™ platform, reported net losses of $22.3 million and $47.5 million for the three and six months ended June 30, 2026. Operating expenses were driven by research and development of TX45 and TX2100 and expanding general and administrative infrastructure; the company has not yet generated product revenue.
Cash and cash equivalents were $227.1 million as of June 30, 2026, with an accumulated deficit of $270.3 million. Tectonic raised additional capital by selling 432,306 shares through its at the market offering for gross proceeds of $13.4 million and net proceeds of $13.1 million. Management believes existing cash will fund operations for at least 12 months.
Clinically, the TX45 APEX Phase 2 trial in PH-HFpEF completed enrollment of 191 patients across 14 countries, about 72% with baseline pulmonary vascular resistance above 3 WU; an independent monitoring committee recommended continuation without modification, and topline data are expected early in the first quarter of 2027. A separate Phase 2 trial in PH-ILD started in March 2026. TX2100 for hereditary hemorrhagic telangiectasia is in an ongoing Phase 1a healthy volunteer study, with six single-dose cohorts dosed and topline results expected by the end of the third quarter of 2026.
Tectonic Therapeutic, Inc. reported financial results for the quarter and six months ended June 30, 2026 and highlighted progress in its clinical pipeline. Enrollment in the global APEX Phase 2 trial of TX45 in PH-HFpEF was completed, with topline results expected in early Q1 2027. The company also completed dosing of single-dose cohorts in the TX2100 Phase 1a trial; subject to favorable data, it plans Phase 1b and Phase 2 studies in hereditary hemorrhagic telangiectasia.
For Q2 2026, research and development expense was $18,048 thousand and general and administrative expense was $6,170 thousand, for total operating expenses of $24,218 thousand. Net loss was $22,285 thousand, or $1.18 per share, compared with $19,984 thousand, or $1.07 per share, a year earlier. For the first six months of 2026, net loss was $47,526 thousand. As of June 30, 2026, cash and cash equivalents were $227,068 thousand, total assets were $237,034 thousand, and stockholders’ equity was $223,846 thousand.
Tectonic Therapeutic Chief Scientific Officer Peter McNamara exercised options for 172 shares of common stock at $14.71 per share and the same day sold 172 shares in an open-market trade at $35.00 per share under a pre-arranged Rule 10b5-1 plan. Following these transactions, he directly holds 55,285 common shares and 7,873 employee stock options, indicating a small, routine liquidity event relative to his overall position.
Tectonic Therapeutic, Inc. Chief Executive Officer Alise Reicin reported routine share movements related to equity compensation. The company withheld 924 shares of Common Stock at $30.34 per share to cover her tax obligations when restricted stock units granted on December 4, 2024 vested and settled. After this tax-withholding disposition, she directly holds 310,623 shares of Common Stock. A separate entry shows 127,030 shares held indirectly through the Reicin-Boiarsky Family Trust, where she may share voting and dispositive power but disclaims beneficial ownership beyond her pecuniary interest. These events reflect compensation mechanics rather than open-market buying or selling.